Company intelligence / Profile preview

Nicox S.A.

Sophia Antipolis, Francenicox.com ↗

Ownership: Public · ALXP
Development stage: Phase 3

Overview

Lead program NCX 470 is in Phase 3 clinical development for glaucoma. In clinical trials, NCX 470 demonstrated superior IOP lowering compared to latanoprost by up to 1.0 mmHg, with ocular hyperemia as the most common adverse event (11.9% vs 3.3% for latanoprost)[4]. The company has two FDA-approved products already commercialized in the US: VYZULTA for glaucoma and ZERVIATE for allergic conjunctivitis[1][2].

Therapeutic areas: OphthalmologyImmunology
Modalities: Small moleculesnitric oxide-donating compounds
Industry: Biotech

Drug pipeline

18 assets

naproxcinod

17 more assets in the full pipeline.

Request access →

Partnerships

Bausch & LombHarrow Inc. (formerly Eyevance Pharmaceuticals)Ocumension Therapeutics

Beyond the preview

Go deeper on Nicox S.A..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nicox S.A..

Explore the full profile